Parkman Healthcare Partners LLC Sells 247,167 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Parkman Healthcare Partners LLC cut its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,881 shares of the biotechnology company’s stock after selling 247,167 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.10% of BioCryst Pharmaceuticals worth $1,631,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Xponance Inc. lifted its position in BioCryst Pharmaceuticals by 9.1% during the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,242 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock valued at $430,000 after acquiring an additional 1,537 shares during the last quarter. Mariner LLC increased its stake in BioCryst Pharmaceuticals by 32.1% during the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 3,224 shares during the last quarter. Arizona State Retirement System raised its position in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Arizona State Retirement System now owns 57,001 shares of the biotechnology company’s stock valued at $429,000 after purchasing an additional 3,518 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 43,920 shares of the biotechnology company’s stock valued at $330,000 after purchasing an additional 4,129 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 price target (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Barclays raised their price objective on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $16.56.

BioCryst Pharmaceuticals Trading Down 2.7%

Shares of NASDAQ BCRX opened at $10.06 on Wednesday. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -16.49 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 12 month low of $5.35 and a 12 month high of $11.11. The company has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $7.92.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the previous year, the company posted $0.28 EPS. The company’s quarterly revenue was up 40.8% on a year-over-year basis. Analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.